ZOOZ to become the first Nasdaq and TASE dual-listed company to hold Bitcoin in its treasury The Board of Directors of the Company has approved the new strategy, which provides investors with exposure to Bitcoin Jordan Fried to become CEO to lead the first Israeli digital asset treasury strategy Largest offering by a Non-US Listed Company to launch a digital asset treasury strategy TEL AVIV, Israel, July 29, 2025 (GLOBE NEWSWIRE) -- ZOOZ Power Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today an ...

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk’s executive vice president of International Operations, has a strong track record of creating ...

Novo Nordisk lowers its financial forecast in a surprise update, citing lagging sales of its weight-loss drug Wegovy as it fights to regain its leading position in the obesity market https://t.co/LeXFsFYwwh ...

LONDON, July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025.Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable servic ...

For investors seeking momentum, Technology Select Sector SPDR ETF (XLK) is probably on the radar. The fund just hit a 52-week high and is up 52.5% from its 52-week low of $172.45 per share. But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:XLK in FocusThe underlying Technology Select Sector Index includes companies from the following industries: computers & peripherals; software; diversified telecomm ...

Spotify shares dropped about 4% Tuesday after the music streaming platform fell short of Wall Street's expectations and posted weak guidance for the current quarter.Here's how the company did versus LSEG estimates:Loss: Loss of .42 euros vs earnings of 1.90 euros per share expectedRevenue: 4.19 billion euros vs. 4.26 billion expectedThe Sweden-based music platform's revenues rose 10% from about 3.81 billion euros in the year-ago period. The company posted a net loss of 86 million euros, or a loss of .42 eur ...

Hypercharge Reports Fourth Quarter and Full Year Fiscal 2025 ResultsJuly 29, 2025 7:30 AM EDT | Source: Hypercharge Networks Corp.Delivered a Record 2,459 Charging Ports, +305% Year-Over-YearRecognized Record Revenue of $10.1 Million, +227% Year-Over-YearAnnual Gross Profit Record of $2.3 Million, +131% Year-Over-Year▶ WATCH - Hypercharge Fiscal 2025 Results Presentation:https://www.youtube.com/watch?v=0iO4W624D4c Vancouver, British Columbia--(Newsfile Corp. - July 29, 2025) - Hypercharge Netw ...

SAN JOSE, Calif., July 29, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a developer of embedded FPGA (eFPGA) IP and ruggedized FPGAs and Endpoint AI solutions, today announced that it has scheduled a conference call to discuss its second quarter fiscal 2025 financial results on Tuesday, August 12, 2025.Date: Tuesday, August 12, 2025Time: 5:30 p.m. ET/2:30 p.m. PTDial-in: Toll Free: 1-877-407-0792; International: 1-201-689-8263Passcode: No passcode neededReplay: (844) 512-2921; Passcode: 13755 ...

NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August.Oppenheimer's 2025 Biotech in the Be ...

- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment -- Plasma and CSF biomarkers support zervimesine’s impact on Alzheimer’s disease biology - PURCHASE, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, presente ...